These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38254778)
41. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. Amaral TMS; Hoffmann MC; Sinnberg T; Niessner H; Sülberg H; Eigentler TK; Garbe C Eur J Cancer; 2020 Jan; 125():38-45. PubMed ID: 31838403 [TBL] [Abstract][Full Text] [Related]
42. Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma and Specification of Benefit of Adjuvant Radiation Therapy. Arron ST; Cañueto J; Siegel J; Fitzgerald A; Prasai A; Koyfman SA; Yom SS Int J Radiat Oncol Biol Phys; 2024 Nov; 120(3):760-771. PubMed ID: 38810706 [TBL] [Abstract][Full Text] [Related]
43. Clinical Utility of Dermoscopy and 31-Gene Expression Profiling by Dermatology Providers in Melanoma Management Care. Witkowski A; Lee C; Latour E; Vetto J; Ludzik J J Drugs Dermatol; 2022 Dec; 21(12):1347-1352. PubMed ID: 36468965 [TBL] [Abstract][Full Text] [Related]
44. Use of the 31-Gene Expression Profile Test to Aid in the Decision of Adjuvant Treatment of Cutaneous Melanoma. Hunt J J Adv Pract Oncol; 2024 May; 15(4):277-280. PubMed ID: 39301099 [TBL] [Abstract][Full Text] [Related]
45. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204 [TBL] [Abstract][Full Text] [Related]
46. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. Kanaki T; Stang A; Gutzmer R; Zimmer L; Chorti E; Sucker A; Ugurel S; Hadaschik E; Gräger NS; Satzger I; Schadendorf D; Livingstone E Eur J Cancer; 2019 Sep; 119():18-29. PubMed ID: 31401470 [TBL] [Abstract][Full Text] [Related]
47. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. Jarell A; Gastman BR; Dillon LD; Hsueh EC; Podlipnik S; Covington KR; Cook RW; Bailey CN; Quick AP; Martin BJ; Kurley SJ; Goldberg MS; Puig S J Am Acad Dermatol; 2022 Dec; 87(6):1312-1320. PubMed ID: 35810840 [TBL] [Abstract][Full Text] [Related]
48. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study. Podlipnik S; Carrera C; Boada A; Richarz NA; López-Estebaranz JL; Pinedo-Moraleda F; Elosua-González M; Martín-González MM; Carrillo-Gijón R; Redondo P; Moreno E; Malvehy J; Puig S J Eur Acad Dermatol Venereol; 2019 May; 33(5):857-862. PubMed ID: 30702163 [TBL] [Abstract][Full Text] [Related]
49. Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series. Au JH; Hooper PB; Fitzgerald AL; Somani AK Dermatol Ther (Heidelb); 2022 Feb; 12(2):591-597. PubMed ID: 34951694 [TBL] [Abstract][Full Text] [Related]
50. Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients. Ballhausen A; Urias E; Gruschkus SK; Williams M; Glover MS; Qin Y; Gombos DS; Patel SP Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209210 [TBL] [Abstract][Full Text] [Related]
51. Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. Bajaj S; Donnelly D; Call M; Johannet P; Moran U; Polsky D; Shapiro R; Berman R; Pavlick A; Weber J; Zhong J; Osman I J Natl Cancer Inst; 2020 Sep; 112(9):921-928. PubMed ID: 31977051 [TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. Gambichler T; Tsagoudis K; Kiecker F; Reinhold U; Stockfleth E; Hamscho R; Egberts F; Hauschild A; Amaral T; Garbe C Eur J Cancer; 2021 Jan; 143():11-18. PubMed ID: 33278769 [TBL] [Abstract][Full Text] [Related]
53. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086 [TBL] [Abstract][Full Text] [Related]
54. Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanoma. Meyer S; Buser L; Haferkamp S; Berneburg M; Maisch T; Klinkhammer-Schalke M; Pauer A; Vogt T; Garbe C Eur J Cancer; 2023 Mar; 182():77-86. PubMed ID: 36753835 [TBL] [Abstract][Full Text] [Related]
55. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. Wysong A; Newman JG; Covington KR; Kurley SJ; Ibrahim SF; Farberg AS; Bar A; Cleaver NJ; Somani AK; Panther D; Brodland DG; Zitelli J; Toyohara J; Maher IA; Xia Y; Bibee K; Griego R; Rigel DS; Meldi Plasseraud K; Estrada S; Sholl LM; Johnson C; Cook RW; Schmults CD; Arron ST J Am Acad Dermatol; 2021 Feb; 84(2):361-369. PubMed ID: 32344066 [TBL] [Abstract][Full Text] [Related]
56. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study. Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959 [TBL] [Abstract][Full Text] [Related]
57. Management of melanoma: can we use gene expression profiling to help guide treatment and surveillance? Zager JS; Hyams DM Clin Exp Metastasis; 2024 Aug; 41(4):439-445. PubMed ID: 38064126 [TBL] [Abstract][Full Text] [Related]
58. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test. Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144 [TBL] [Abstract][Full Text] [Related]
59. Using Gene Expression Profiling to Personalize Skin Cancer Management. LeQuang JA J Clin Aesthet Dermatol; 2022 Nov; 15(11 Suppl 1):S3-S15. PubMed ID: 36405422 [TBL] [Abstract][Full Text] [Related]
60. Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group. Farberg AS; Marson JW; Glazer A; Litchman GH; Svoboda R; Winkelmann RR; Brownstone N; Rigel DS; Dermatol Ther (Heidelb); 2022 Apr; 12(4):807-823. PubMed ID: 35353350 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]